newsfilter
← Latest News
Business Wire·

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash Strengthened balance